ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

3.890

+0.080 (2.10%)

At close: Nov 13, 2026, 4:00 PM EST

3.850

-0.040 (-1.03%)

After-hours: Nov 13, 2026, 7:30 PM EST

ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	25.62	41.32	50.82	70.97	210.52	60.06
Short-Term Investments	112.73	203.67	263.21	157.39	63.86	-
Cash & Short-Term Investments	138.35	244.99	314.02	228.36	274.38	60.06
Cash Growth	-52.00%	-21.98%	37.51%	-16.77%	356.82%	144.94%
Accounts Receivable	52.76	25.35	8.18	-	-	-
Other Receivables	0.5	1	1	0.69	1.01	0
Receivables	53.26	26.35	9.18	0.69	1.01	0
Inventory	11.71	8.37	5.21	-	-	-
Prepaid Expenses	7.71	5.19	5.89	2.03	2.31	0.67
Other Current Assets	-	-	-	0.65	-	-
Total Current Assets	211.03	284.9	334.3	231.73	277.7	60.73
Property, Plant & Equipment	1.93	2.47	1.07	0.82	0.77	0.69
Other Intangible Assets	13.62	14.45	7.37	0.62	-	-
Other Long-Term Assets	24.91	25.84	8.42	0.02	2.96	0.02
Total Assets	251.48	327.65	351.15	233.19	281.44	61.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.42	9.16	14.13	0.76	1.66	1.79
Accrued Expenses	26.2	10.05	2.47	0.36	2.1	1.3
Current Portion of Long-Term Debt	-	-	-	-	-	3.48
Current Portion of Leases	-	-	-	0.24	0.23	0.14
Current Income Taxes Payable	-	-	-	-	0.17	-
Current Unearned Revenue	0.51	0.61	0.56	-	0.28	1.46
Other Current Liabilities	32.77	19.33	6.29	1.04	1	0.02
Total Current Liabilities	64.9	39.15	23.44	2.39	5.44	8.19
Long-Term Debt	197.02	168.51	69.38	-	-	4.93
Long-Term Leases	-	-	-	0.04	0.25	0.48
Long-Term Unearned Revenue	1.05	1.13	1.53	-	2.85	3
Other Long-Term Liabilities	0.47	4.61	-	-	-	0.08
Total Liabilities	263.44	213.39	94.36	2.43	8.55	16.68

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	441.29	408.73	379.87	362	349.41	10.98
Retained Earnings	-453.15	-294.6	-123.31	-131.3	-76.94	-42.26
Comprehensive Income & Other	-0.1	0.13	0.22	0.05	0.41	-
Total Common Equity	-11.96	114.26	256.8	230.76	272.89	-31.27
Shareholders' Equity	-11.96	114.26	256.8	230.76	272.89	44.77
Total Liabilities & Equity	251.48	327.65	351.15	233.19	281.44	61.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	197.02	168.51	69.38	0.27	0.48	9.03
Net Cash (Debt)	-58.66	76.47	244.64	228.09	273.9	51.03
Net Cash Growth	-	-68.74%	7.26%	-16.73%	436.74%	251.86%
Net Cash Per Share	-0.59	0.78	2.39	2.40	6.86	1.77
Filing Date Shares Outstanding	100.53	99.3	98.12	96.5	94.4	25.7
Total Common Shares Outstanding	100.25	99.29	97.95	96.41	93.94	25.7
Working Capital	146.13	245.75	310.86	229.34	272.26	52.54
Book Value Per Share	-0.12	1.15	2.62	2.39	2.90	-1.22
Tangible Book Value	-25.58	99.81	249.43	230.14	272.89	-31.27
Tangible Book Value Per Share	-0.26	1.01	2.55	2.39	2.90	-1.22
Machinery	-	-	-	0.67	0.38	0.09
Leasehold Improvements	-	-	-	0.02	-	-

SEC Filings: 10-K · 10-Q